St. Jude launches PAD device in India; InVivo wins FDA nod for U.S. trial;

@FierceMedDev: St. Jude faces fresh crop of Riata suits. Story | Follow @FierceMedDev

@MarkHFierce: David vs Goliath (J&J). David won. And then he lost on appeal. More | Follow @MarkHFierce

 @DamianFierce: Cancer Genetics is finally going public--at about 14% of its preliminary IPO pricing. News | Follow @DamianFierce

> Foundation Medicine has signed on to handle companion diagnostics for Agios Pharmaceuticals' cancer therapies. Article

> InVivo Therapeutics ($NVIV), won the FDA's blessing to kick off human studies in the U.S. of its biopolymer scaffold to treat spinal cord injuries. News

> St. Jude Medical ($STJ) has launched its PAD-treating Ilumien PCI device in India. Story

> PeriGen, maker of fetal surveillance devices, has raised $6.4 million in venture cash to boost its market adoption. More

> Terumo inked a multi-year distribution agreement with Nonin Medical to market that company's Equanox Model 7600 Regional Oximetry System to cardiovascular hospitals in the U.S. Item

> CryoLife won 510(k) clearance for a next-generation kidney dialysis device. Story

> Senate Republicans were hoping their House counterparts would pass a standalone medical device tax repeal bill, but Roll Call reports representatives would prefer to roll the effort into broad tax reform legislation. Report

Biotech News

@FierceBiotech: In case you missed it yesterday: Fierce's 10 top biotech billionaires. Special report | Follow @FierceBiotech

@JohnCFierce: Receptos--experienced team with CEO Faheem Hasnain (Facet)--files for IPO. S-1 | Follow @JohnCFierce.

@RyanMFierce: Looks like BMY and VRTX have struck another let's-see-what-happens deal in Hep C. Phase II only pact for now. Release | Follow @RyanMFierce

> Sarepta sustains high hopes for DMD drug eteplirsen with more PhII data. Article

> AstraZeneca reports hit-and-miss PhIII for arthritis pill. Report

> Astellas, Ambrx seal $300M cancer ADC deal. News

Pharma News

@FiercePharma: India's top court rebuffs Merck, lets generic Januvia roll despite patent, at least for now. More | Follow @FiercePharma

@EricPFierce: FDA has no comment on judge's ruling to make Teva's Plan B available OTC to adolescents. Story | Follow @EricPFierce

> Roche's Tamiflu, GSK's Relenza work against new bird flu strain. Item

> Pfizer needs consumer unit as pipeline in prescription to OTC trend. Article

> IMS sees little drug spending impact from shift to managed Medicaid plans. Report

Suggested Articles

The former CEO of the molecular testing company Foundation Medicine, Troy Cox, has been named chairman of the Swiss big data firm Sophia Genetics.

Researchers at MIT used a machine-learning algorithm to uncover the potent antibiotic properties hiding within an old small-molecule candidate.

The randomized, blinded study showed statistically significant improvements in assessments of inattention and brain activity.